Abstract
2-Butoxyethanol (BE) is widely used as a solvent in coatings and other consumer products and has shown hematotoxicity in laboratory animals. To provide a physiological basis for extrapolating toxicokinetic data observed in rats to humans, a blood flow rate-limited, physiologically based pharmacokinetic model was developed to describe the distribution and metabolism of BE in rats following drinking water, dermal, and inhalation exposures. The major urinary metabolite, butoxyacetic acid, represented 45 to 60% of the absorbed dose in all three routes of exposure. Other identified urinary metabolites in our studies included ethylene glycol and BE-glucuronide. A model formulation of the possible metabolic pathways based on the experimental data was proposed. The amounts of individual urinary metabolites were used to develop the model. Metabolic constants were estimated by fitting the data within the constraints of in vitro measurements. The model explained the change of profiles of urinary metabolites in different exposure routes by taking into account the differences in absorption rate and by incorporating a minor pathway for metabolism by skin. Sensitivity analysis showed that metabolic constants and blood flow rate to liver had a relatively larger influence on the production of urinary metabolites than the organ volume or the partition coefficient for BE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
